Dishman Pharmaceuticals posted a 13.24% topline growth in the fourth quarter of FY12 and reported a consolidated net profit of Rs 312.94 million for the quarter ended 31 March, 2012, up 37.30% from Rs 227.92 million in the corresponding quarter last year.
first published: May 15, 2012 04:33 pm
A collection of the most-viewed Moneycontrol videos.
Groww CEO Lalit Keshre on ₹62,000 Crore IPO, Sebi regulations, valuation expectation and more
How Income Plus Arbitrage Fund of Fund Can Help You Get Stable, Tax-Efficient Returns
Nifty fails to hold 26,000, slips below 25,900 | Closing Bell
Live: Will Nifty bulls take it to new highs after Fed outcome? | Opening Bell
